Prempro

They were older, an average of 62.7, which put them at a greater risk of cardiovascular problems.Klaiber says earlier studies showing that cyclical hormones protect against heart disease are probably valid, and he's hoping that a multicenter trial will show that HRT is not risky in women just beginning to go through menopause.

To learn more visit myDNA's Pharmacogenomics Center Read More Reviewed: December 21, 2005 Rick Nauert PhD Source: Revolution Health News Copyright: ©Revolution Health Group Email: advertisement advertisement Home - Search - About Us - Advertise - Policies - Syndication Site Last Updated: December 21, 2005 Copyright © 2005 Revolution Health Group, LLC.

All medical and health content provided on the myDNA.com website has been reviewed by its Chief Medical Officer.

Where the website contains links to other sites, Revolution Health Group, LLC is not responsible for either the privacy practices or the content of such web sites.

The information provided is for general information only and is not intended to replace the advice of your h...

So instead of HRT, "which scares me," Ms.

Smith now takes 1,000 milligrams a day of Vitamin E, which she believes help alleviate her symptoms.

As Ms.

Smith found, it comes down to balancing risk versus quality of life.

"I think you have to work with a patient's belief structure, her personal mythology," Dr.

Minkin said.

"I'm perhaps a little fringe-ier than most, but I just give them all the pros and cons and let them make the decision." "HRT does work the best, but the key idea here is, it's not the only option," said Dr.

Minkin.

Indeed, for people like Barb Pionati, HRT remains the only game in town.

An oncology nurse who experienced menopause in her mid-thirties, Ms.

Pionati was startled to read the results of the WHI study.

After her gynecologist laid out the data in more detail, she decided to stay on HRT.

"I felt it was worth the risks in terms of quality of life issues," said Ms.

Pionati, of Point Breeze.

She has stayed with hormones "because with them, I have a brain, and I have a sex life." That's an attitude that Dr.

Portman encounters frequently in her practice among women who have been told by other doctors they won't prescribe HRT.

"They say, 'If you tell me you're not going to prescribe this, I'm going to find someone else who ...

The highly competitive market has triggered several lawsuits, making them an integral part of the global generic drug business due to the high stakes involved.

A company like Ranbaxy spent about $20 million on cases of patent challenges last year.

Analysts feel that companies would not shy away from litigation because of the size of the gains in case of a win.

They said the patent portfolio of some of the traditional pharmaceutical companies indicate that their in-house technical competence is inadequate to meet the threat from global generic drug manufacturers such as Ranbaxy, which are fiercely targeting the large domain of off-patent drugs.

Analysts said in the new regime, several Indian companies have shown signs of a transition from being generic drug manufacturers to innovators.

These firms are also focusing on basic research in search for new molecules.

More stories in Business • Nath clears air on trade-off • China pulls past Italy, Britain next • Posco port in choppy seas • Reliance gas deal in court • REL to invite bids for Dadri project • Kyrgyzstan rolls out welcome mat • Tata Motors arms on fast track • AIG set to float asset company • AirTel broadband service in east soon • New has its own Apeal • NMCE banks ...